Drug-delivery strategies using biomaterials in the field of nerve regeneration
Xu L., Zhou C., Wang X., Fan C.
Laboratory Study, published in Neural Regen Res (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Neural Regen Res (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40536924
- PMCID
- PMC12694642
- DOI
- 10.4103/nrr.nrr-d-25-00027
- Citations
- 3
Abstract (original English)
Neural injuries can cause considerable functional impairments, and both central and peripheral nervous systems have limited regenerative capacity. The existing conventional pharmacological treatments in clinical practice show poor targeting, rapid drug clearance from the circulatory system, and low therapeutic efficiency. Therefore, in this review, we have first described the mechanisms underlying nerve regeneration, characterized the biomaterials used for drug delivery to facilitate nerve regeneration, and highlighted the functionalization strategies used for such drug-delivery systems. These systems mainly use natural and synthetic polymers, inorganic materials, and hybrid systems with advanced drug-delivery abilities, including nanoparticles, hydrogels, and scaffold-based systems. Then, we focused on comparing the types of drug-delivery systems for neural regeneration as well as the mechanisms and challenges associated with targeted delivery of drugs to facilitate neural regeneration. Finally, we have summarized the clinical application research and limitations of targeted delivery of these drugs. These biomaterials and drug-delivery systems can provide mechanical support, sustained release of bioactive molecules, and enhanced intercellular contact, ultimately reducing cell apoptosis and enhancing functional recovery. Nevertheless, immune reactions, degradation regulation, a
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.